| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a904da1536b38e2d48c8541c069149d4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2022-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eb4c3cb94a6d9633a22c48e4b90f5aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d6a2686df8b3c1ad6d56dfe03764184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_540db4758725a4bb996b7becc3bbed8f |
| publicationDate |
2022-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022214089-A1 |
| titleOfInvention |
Cellular immunotherapy use |
| abstract |
A cancer treatment composition and a cancer treatment method. Provided are a cancer treatment method and a treatment composition for patients for whom an anti-PD-1 antibody or anti-PD-L1 antibody treatment has failed. |
| priorityDate |
2021-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |